Systemic Anti-Cancer Therapy Regimen Library
PCN MM - zoledronic acid [Q4W]
Treatment Overview
Cycle 1 (and all further cycles) - 28 days
Consider appropriate dose modification for patients with reduced creatinine clearance.
Consider oral supplementation of at least 500 mg elemental calcium daily and vitamin D equivalent to 400 units daily (e.g. colecalciferol 1.25 mg orally ONCE a month) for the duration of treatment.
Dental check-up recommended prior to starting, and at 6-monthly intervals during treatment. Patients should be encouraged to maintain good oral hygiene and report any adverse oral symptoms.
Cycle details
Cycle 1 (and all further cycles) - 28 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| zoledronic acid | 4 mg | intravenous | 1 | Min: 15 minutes |
Consider appropriate dose modification for patients with reduced creatinine clearance.
Consider oral supplementation of at least 500 mg elemental calcium daily and vitamin D equivalent to 400 units daily (e.g. colecalciferol 1.25 mg orally ONCE a month) for the duration of treatment.
Dental check-up recommended prior to starting, and at 6-monthly intervals during treatment. Patients should be encouraged to maintain good oral hygiene and report any adverse oral symptoms.
Full details
Cycle 1 (and all further cycles) - 28 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| zoledronic acid | 4 mg | intravenous | Min: 15 minutes |
Instructions:
|
Supportive Care Factors
No supportive care factors specified
References
Berenson JR, Meletios A and Dimopoulos MD. 2006 "Zoledronic Acid May Improve Survival Compared to Pamidronate in Patients with MM and High BALP Levels..." Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 3589.
Viatris Limited New Zealand. Zoledronic acid Viatris (zoledronic acid) New Zealand Datasheet 10 November 2022. https://www.medsafe.govt.nz/profs/datasheet/z/ZoledronicAcidinf.pdf (Accessed 25 June 2024)
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.